|

Azithromycin for Critical Asthma - Pediatrics

RECRUITINGPhase 2/3Sponsored by Johns Hopkins All Children's Hospital
Actively Recruiting
PhasePhase 2/3
SponsorJohns Hopkins All Children's Hospital
Started2024-04-02
Est. completion2026-07-31
Eligibility
Age3 Years – 17 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06223828

Summary

The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.

Eligibility

Age: 3 Years – 17 YearsHealthy volunteers accepted
Inclusion criteria

* Age 3-17 years
* Admission to the PICU
* Primary diagnosis of critical asthma
* Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
* Prescription for intravenous systemic corticosteroids

Exclusion criteria

* Critical Congenital Heart Disease Unrepaired
* Tracheostomy Dependence at Admission
* Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
* Past Medical History of Prolonged QT Syndrome or Arrhythmias
* Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension

Conditions3

AsthmaCritical IllnessPediatric Asthma

Locations1 site

Johns Hopkins All Children's Hospital
St. Petersburg, Florida, 33701
Anthony A Sochet, MD727-767-2912sochet@jhmi.edu

Browse More Trials

Asthma trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.